Reviva Pharmaceuticals (RVPH) - 2024 Q4 - Annual Results

Exhibit 99.1 Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights – Favorable long-term safety and robust broad-spectrum ef icacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 – – Full data set from RECOVER OLE expected in Q2 2025 –– Cupertino, Calif., March 31, 2025 – Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a l ...